Contact: Elaine Vitone
Mobile: 412-925-0320
E-mail: vitoneeg@upmc.edu
Contact: Kaleigh Connors
Mobile: 412-846-0647
E-mail: ConnorsKa3@upmc.edu
PITTSBURGH, Oct. 7, 2026 – Scientists have taken another important step toward vision restoration in people with certain inherited forms of blindness. In a study published today in the New England Journal of Medicine , researchers at the University of Pittsburgh School of Medicine and international collaborators showed that an experimental, optogenetics-based treatment was safely administered to 10 patients and improved visual function in some participants when used in combination with a specially designed visual stimulation device.
The retina, a thin layer of tissue at the back of the eye that captures light and sends visual information to the brain, is a part of the central nervous system—thus, unlike many other tissues in the body, is limited in its ability to repair itself. Retinitis pigmentosa (RP), which destroys light-sensing cells in the retina, affects more than 1.5 million people worldwide. At onset, patients first notice impaired night vision, then impaired peripheral vision that gradually worsens over time, which can ultimately lead to severe vision loss or blindness.
“Retinitis pigmentosa can result from a mutation in any one of more than 100 distinct genes, so it presents an extraordinary challenge,” said José-Alain Sahel, M.D. , distinguished professor and chair of the Department of Ophthalmology at Pitt, director of the UPMC Vision Institute and first and co-corresponding author of the study. While in recent years Sahel and others have made strides in stopping and even reversing other progressive blinding diseases using gene therapies that target specific disease-causing mutations, RP requires an outside-of-the-box approach.
“Developing a separate treatment for every genetic cause of retinitis pigmentosa is proving tremendously difficult and costly. While we continue working on correcting specific gene defects, our goal is to develop a way to restore visual function regardless of which gene caused the disease," said Sahel.
In optogenetics, scientists alter cells to produce light-sensing proteins, which they are working to modulate for a variety of experimental uses. In this study, the team delivered a gene that produces a light-sensing protein known as ChrimsonR into surviving retinal ganglion cells, via a single injection into the eye.
The protein is then put into action with a visual prosthetic system. The user wears specialized goggles with a built-in camera that sends visual information to a portable processor. The processor, in turn, converts the information into patterns of light. A projector within the glasses sends back to the eye these patterns of light, which are of specific wavelengths designed to activate ChrimsonR in the modified retinal cells.
The researchers administered the optogenetic treatment to 10 people with advanced retinitis pigmentosa who were legally blind with little or no remaining vision. In this small, early-stage trial, the team found encouraging results in tests of the treatment’s safety.
Most eye-related side effects were mild or moderate and included temporary inflammation and short-lived increases in eye pressure.
After treatment, seven of the 10 participants had improved light sensitivity, and six made gains large enough to be considered clinically meaningful. While the treatment did not restore normal vision or the ability to read, some participants became better able to detect when an object was present, determine where it was located and reach toward it accurately while using the goggles.
The team also tested whether visual information was reaching the brain. Using electroencephalography (EEG), researchers led by Marlene Behrmann, Ph.D., professor of ophthalmology at Pitt, found evidence that visual signals reached and were processed by the visual cortex when participants viewed objects. Four participants showed consistent improvements across multiple real-world visual tasks over months to years of testing.
"These results show that even in people with profound vision loss, the visual system retains a remarkable capacity to process new information," said Sahel. “Potentially, the approach could also help patients with other blinding diseases in which the eye's light-sensing cells have been lost, but other retinal cells—especially retinal ganglion cells—remain viable. Many of these patients currently have few or no treatment options.”
The study builds on a landmark Nature Medicine paper published in 2021, the first report of partial recovery of visual function in a blind patient following optogenetic therapy and the first ever clinical application of optogenetics in medicine. Last month, Sahel and his longtime collaborator, Botond Roska, M.D., Ph.D., of the Institute of Molecular and Clinical Ophthalmology Basel, who is also corresponding author of the current study, received the António Champalimaud Vision Award , the largest award in the field, for their contribution to vision restoration research.
The findings of the new study highlight one of several promising and complementary strategies the team is pursuing to restore vision in patients with end-stage retinal disease. Last year, Sahel was senior author of a New England Journal of Medicine article describing the ability to restore vision using an implanted prosthetic in patients affected with end-stage, age-related macular degeneration. The technology , known as PRIMA, has since received permission from the European Union to be marketed for clinical use within many European countries.
Additional authors on the current study were Joseph N. Martel, M.D., Shouyu Ling, Ph.D., Dana Aravich, M.S., and William Smith, O.D., all of the University of Pittsburgh, UPMC or both; Isabelle Audo, M.D., Ph.D., Angelo Arleo, Ph.D., Jean-Baptiste de Saint Aubert, Ph.D., Alexandre Delaux, Ph.D., and Antonin Duret, M.S., of Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique and Institut de la Vision, Paris; Elise Boulanger-Scemama, M.D., of L’Hôpital Fondation Adolphe de Rothschild, Paris; Stefan Futterknecht, M.D., of Institute of Molecular and Clinical Ophthalmology Basel and University of Basel, Department of Ophthalmology, Basel, Switzerland; Chloé Pagot, Ph.D., Cécilia Coen, C.O., and Caroline de Montleau, C.O., of Streetlab, Paris; Simona Degli Esposti, M.D., of Moorfields Eye Hospital NHS Foundation Trust, London; Cecile Hayem, M.S., of Acefas, Paris; and Magali Taiel, M.D., of GenSight Biologics, Paris.
This research was supported by GenSight Biologics and conducted as part of the PIONEER clinical trial (NCT03326336).
# # #
About the University of Pittsburgh School of Medicine
As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top recipients of funding from the National Institutes of Health since 1998. In rankings released by the National Science Foundation, Pitt is in the upper echelon of all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC , which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see www.medschool.pitt.edu .
About UPMC
UPMC is a world-renowned, nonprofit health care provider and insurer committed to delivering exceptional, people-centered care and community services. Headquartered in Pittsburgh and affiliated with the University of Pittsburgh Schools of the Health Sciences, UPMC is shaping the future of health through clinical and technological innovation, research, and education. Dedicated to advancing the well-being of our diverse communities, we provide nearly $2 billion annually in community benefits, more than any other health system in Pennsylvania. Our 100,000 employees — including more than 5,000 physicians — care for patients across more than 40 hospitals and 800 outpatient sites in Pennsylvania, New York, Ohio and Maryland, as well as overseas. UPMC Insurance Services covers 4 million members, providing affordable, high-quality, value-based care. To learn more, visit UPMC.com.
New England Journal of Medicine
Randomized controlled/clinical trial
People
Optogenetic Therapy for Restoring Aspects of Visual Function
7-Oct-2026
A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by GenSight Biologics. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.